TOKYO -- Japan's Takeda Pharmaceuticals has drawn closer to offering a first-of-its-kind treatment for narcolepsy, with the final phase of clinical studies set to launch this fall.
Pharmaceuticals
Japan's Takeda nears breakthrough in treating narcolepsy
Final clinical trials to start in fall for drug with $1bn blockbuster potential
Takeda says that its TAK-861 drug candidate has the potential to address the full spectrum of narcolepsy symptoms. (Takeda)
Read Next
.JPG?width=178&fit=cover&gravity=faces&dpr=2&quality=medium&source=nar-cms&format=auto&height=100)
Latest on Pharmaceuticals
